ARGX:NSD-argenx SE (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 255.37

Change

+6.80 (+2.74)%

Market Cap

USD 11.82B

Volume

0.09M

Average Target Price

USD 243.50 (-4.65%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.45 (-0.17%)

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-2.14 (-0.37%)

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

+5.56 (+3.01%)

USD32.18B N/A N/A
MRNA Moderna, Inc

+1.08 (+1.55%)

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-1.13 (-0.99%)

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

-1.75 (-0.62%)

USD24.87B N/A N/A
RPRX Royalty Pharma plc

+1.14 (+2.85%)

USD24.33B 34.81 9.50
GMAB Genmab A/S

+0.93 (+2.58%)

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

+0.16 (+0.19%)

USD19.73B N/A N/A
INCY Incyte Corporation

+3.81 (+4.40%)

USD18.93B 47.64 35.20

ETFs Containing ARGX

Symbol Name Weight Mer Price(Change) Market Cap
EWK iShares MSCI Belgium Capp.. 0.00 % 0.49 %

+0.30 (+1.82%)

USD0.03B
DX2J:F Xtrackers MSCI Europe Sma.. 0.00 % 0.30 %

+0.77 (+1.80%)

USD0.65B
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.00 % 0.45 %

+1.45 (+2.34%)

USD0.43B
UEFD:XETRA UBS ETF - MSCI EMU Small .. 0.00 % 0.33 %

+1.84 (+2.03%)

USD0.08B
SXRJ:XETRA iShares VII PLC - iShares.. 0.00 % 0.58 %

+3.90 (+2.04%)

USD0.66B
LGWU:XETRA Lyxor Index Fund - Lyxor .. 0.00 % 0.40 %

+5.80 (+2.21%)

USD0.20B
IQQM:XETRA iShares EURO STOXX Mid UC.. 0.00 % 0.40 %

+1.20 (+2.26%)

USD0.32B
DX2J:XETRA Xtrackers MSCI Europe Sma.. 0.00 % 0.30 %

+0.93 (+2.18%)

USD0.65B
ZPRS:F SPDR MSCI World Small Cap.. 0.00 % 0.45 %

+1.32 (+2.13%)

USD0.43B
UEFD:F UBS ETF - MSCI EMU Small .. 0.00 % 0.33 %

+1.69 (+1.87%)

USD0.13B
SXRJ:F iShares VII PLC - iShares.. 0.00 % 0.58 %

+3.40 (+1.78%)

USD0.66B
LGWU:F Lyxor Index Fund - Lyxor .. 0.00 % 0.40 %

+4.55 (+1.73%)

USD0.20B
IQQM:F iShares EURO STOXX Mid UC.. 0.00 % 0.40 %

+0.98 (+1.84%)

USD0.32B
SMC:PA SPDR MSCI Europe Small Ca.. 0.00 % 0.30 %

+4.65 (+2.08%)

USD0.11B
IEUS iShares MSCI Europe Small.. 0.00 % 0.40 %

+0.83 (+1.65%)

USD0.12B
MMS:PA Lyxor Index Fund - Lyxor .. 0.00 % 0.40 %

+5.12 (+1.95%)

USD0.20B
XXSC:LSE Xtrackers MSCI Europe Sma.. 0.00 % 0.30 %

+60.75 (+1.57%)

USD0.65B
WOSC:LSE SPDR MSCI World Small Cap.. 0.00 % 0.45 %

+0.89 (+1.57%)

USD0.43B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.35 %

+0.07 (+1.71%)

USD1.36B
UB69:LSE UBS ETF - MSCI EMU Small .. 0.00 % 0.33 %

+83.50 (+1.00%)

USD0.13B
FEUD:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

+36.00 (+1.36%)

USD0.13B
EUSC:LSE SPDR MSCI Europe Small Ca.. 0.00 % 0.30 %

+3.00 (+1.47%)

USD0.12B
DJMC:LSE iShares EURO STOXX Mid UC.. 0.00 % 0.40 %

+77.75 (+1.61%)

USD0.32B
CES1:LSE iShares VII PLC - iShares.. 0.00 % 0.58 %

+247.00 (+1.42%)

USD0.66B
AADR AdvisorShares Dorsey Wrig.. 0.00 % 1.10 %

+0.71 (+1.31%)

USD0.08B
SCZ iShares MSCI EAFE Small-C.. 0.00 % 0.40 %

+0.99 (+1.71%)

USD8.25B
PIZ Invesco DWA Developed Mar.. 0.00 % 0.81 %

+0.24 (+0.77%)

USD0.17B
1388:TSE UBS ETF - MSCI EMU Small .. 0.00 % 0.33 %

N/A

USD0.13B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 59.09% 81% B- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.09% 81% B- 87% B+
Trailing 12 Months  
Capital Gain 124.09% 85% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 124.09% 85% B 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 77.45% N/A N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.45% N/A N/A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 107.84% N/A N/A 8% F
Risk Adjusted Return 71.82% N/A N/A 84% B
Market Capitalization 11.82B 97% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.05 33% F 21% F
Price / Cash Flow Ratio 87.84 1% F 3% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -28.35% 83% B 32% F
Return on Invested Capital -23.21% 82% B- 27% F
Return on Assets -13.50% 81% B- 24% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.81 42% F 28% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.98 74% C 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector